Investor Alert: Class Action Filed Against Mereo BioPharma Group by Berger Montague

Overview

Berger Montague, a renowned national plaintiffs' law firm, has recently initiated a class action lawsuit against Mereo BioPharma Group PLC (NASDAQ: MREO). This legal action is aimed at investors who acquired Mereo's American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025. The deadline for affected investors to seek appointment as lead plaintiffs in this case is April 6, 2026.

Background

Mereo BioPharma is a London-based biopharmaceutical company focusing on developing treatments for rare and serious diseases. During the class period, the company made several optimistic public statements regarding its ORBIT and COSMIC Phase 3 clinical trials assessing the effectiveness of setrusumab for Osteogenesis Imperfecta, a bone disorder. Unexpectedly, on December 29, 2025, the company revealed that neither trial met its primary endpoint of reducing the annual clinical fracture rate. This disclosure led to a dramatic drop in the price of Mereo's ADS, plummeting more than 87% from $2.31 per share to just $0.29 by December 29, 2025.

Legal Implications

The ramifications of this lawsuit are significant for affected investors. According to Berger Montague, those who purchased securities during the designated period may have recourse to seek justice for the losses incurred due to alleged misleading statements by Mereo. The firm is inviting investors to reach out for more information regarding their rights in this case.

Contact Information

If you are a disgruntled investor looking for more details about your rights and the upcoming legal proceedings, you can contact Berger Montague directly. Andrew Abramowitz and Caitlin Adorni are available for inquiries at their respective phone numbers and email addresses.

About Berger Montague

With over 55 years in complex civil litigation, Berger Montague has an impressive track record, having secured over $50 billion for clients across various legal areas, including class actions, antitrust cases, and consumer protection. The firm is based in Philadelphia but operates numerous offices across the United States and Canada, making it a leading entity in the legal landscape.

Conclusion

This lawsuit serves as a critical reminder for investors regarding the importance of due diligence and the potential consequences when companies make overly optimistic claims. As the case progresses, further developments will emerge, impacting both Mereo and its investors. Those affected are encouraged to act swiftly and consult with Berger Montague to ensure their rights are preserved in this legal battle.